T. Tritton

First name
T.
Last name
Tritton
Czira, A., Requena, G., Banks, V., Wood, R., Tritton, T., Castillo, C. M., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 18, 643-659. http://doi.org/10.2147/copd.s405498
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
Halpin, D. M. G., Rothnie, K. J., Banks, V., Czira, A., Compton, C., Wood, R., et al. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540
Czira, A., Banks, V., Requena, G., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
Requena, G., Banks, V., Czira, A., Wood, R., Tritton, T., Wild, R., et al. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
Webb, J., Mount, J., von Arx, L. B., Rachman, J., Spanopoulos, D., Wood, R., et al. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580
Denee, T., Kerr, C., Ming, T., Wood, R., Tritton, T., Middleton-Dalby, C., et al. (2021). Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study. J Psychiatr Res. http://doi.org/10.1016/j.jpsychires.2021.05.026